- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02010801
Evaluation of Tumor Ablation Effects by Irreversible Electroporation for Patients With Malignant Liver Tumors
Liver cancer including primary hepatocellular carcinoma (HCC) and metastatic liver cancers is one the most common malignancies in the world. Over 10000 new cases per year are diagnosed in Taiwan. Despite the many treatment options, the prognosis of HCC remains dismal. More than 8000 people died of this cancer every year in Taiwan. A majority (70%to 85%) of patients present with advanced or unresectable disease. In contrast, small liver cancers can be cured with an appreciable frequency. Five-year disease-free survival exceeding 50% has been reported for surgical resection, and for the inoperable patients who do not have vascular invasion or extrahepatic spread. Radiofrequency ablation (RFA) is recommended as an alternative curative therapy. However, the main drawback of RFA is its limitation to tumor size and location. The tumors larger than 5 cm in diameter or located adjacent to vessels, could not be ablated completely.
Irreversible electroporation (IRE), developed and manufactured by AngioDynamics US Ltd, can ablate tumor by fenestrating the cancer cell membrane by electric pulse. The anti-tumor effect does not result from thermotherapy, so is also not diminished by adjacent vessels. Several pre-clinical studies have already demonstrated IRE is a safe and effective treatment for live cancers. The system has received CE mark approval in 2008 and FDA approval in 2010. However, there is no experience in using IRE fro tumor ablation in Taiwan. In this study, the investigators will perform intraoperative IRE for the patients with liver cancers who are scheduled to receive hepatectomy in our hospital, and the investigators will evaluate the ablate effect of tumors on specimens, and the effect of adjacent vessels. The investigators will appraisal the clinical feasibility and advantage of the system by this study.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 10002
- National Taiwan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The diagnosis of HCC or other cancers with hepatic metastatic with pathologic proven.
- The diagnosis of HCC will be made by pathology / cytology or according to the AASLD(2010) diagnostic criteria. In brief, Nodules larger than 1 cm found on ultrasound screening of a cirrhotic liver should be investigated further with either 4-phase multidetector CT scan or dynamic contrast enhanced MRI. If the appearances are typical of HCC (i.e., hypervascular in the arterial phase with washout in the portal venous or delayed phase), the lesion should be treated as HCC. If the findings are not characteristic or the vascular profile is not typical, a second contrast enhanced study with the other imaging modality should be performed, or the lesion should be biopsied. Biopsies of small lesions should be evaluated by expert pathologists. Tissue that is not clearly HCC should be stained with all the available markers including CD34, CK7, glypican 3, HSP-70, and glutamine synthetase to improve diagnostic accuracy.
- Suitable for surgical resection, but the distance between tumors and preserved vessels is less than 5 mm. Adequate safe margin can not be obtained.
- There are at least one tumor, but less than or equal to 3 tumors,
- Each tumor must be ≤ 5 cm in diameter,
- Child-Pugh class A-B,
- Eastern Cooperative Oncology Group (ECOG) score of 0-1,
- American Society of Anaesthesiologists (ASA) score ≤ 3,
- Platelet count ≥ 100 K/Μl
- Total bilirubin ≦ 2 mg/dL
- ALT and AST < 5 x upper limit of normal
- PT-INR ≦ 2.0, or PT < 6 seconds above control
- Serum creatinine ≦ 1.5 x upper limit of normal
- Prior Informed Consent Form
- Life expectancy of at least 3 months.
Exclusion Criteria:
- Congestive heart failure >New York Heart Association (NYHA) class 2
- Active coronary artery disease (CAD) (myocardial infarction more than 6 months prior to study entry is allowed)
- Cardiac arrhythmias (>Grade 2 NCI-CTCAE Version 3.0) which are poorly controlled with anti-arrhythmic therapy or requiring pace maker
- Uncontrolled hypertension
- Any active metal implanted device (eg Pacemaker),
- Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
- Received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ IRE System,
- Known history of HIV infection
- Concurrent primary extrahepatic cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IRE for tumor before tumor resection
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Complete treatment
Time Frame: 1 month later
|
1 month later
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
adverse effect
Time Frame: one month
|
one month
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201010036D
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Liver Tumors
-
Taipei Medical University WanFang HospitalCompleted
-
Fudan UniversityRecruiting
-
University Hospital, MontpellierCompleted
-
National Taiwan University HospitalWithdrawnHepatocellular Carcinoma (HCC)Taiwan
-
Peking University Third HospitalRecruitingLiver Function Failure | Liver Malignant TumorsChina
-
Memorial Sloan Kettering Cancer CenterCompletedGastro-enteropancreatic Neuroendocrine Tumor | Secondary Malignant Neoplasm of LiverUnited States
-
Assistance Publique - Hôpitaux de ParisInstitut National de Recherche en Informatique et en AutomatiqueUnknownCirrhosis | Benign Liver Tumor | Malignant Tumor Liver
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedMalignant Tumors | Refractory TumorsFrance
-
Leiden University Medical CenterPhilips Healthcare; European CommissionRecruitingHepatocellular Carcinoma | Liver Metastases | Liver Cancer | Liver Metastasis Colon CancerNetherlands
-
Peking Union Medical College HospitalPeking University; Peking University Cancer Hospital & InstituteRecruiting
Clinical Trials on irreversible electroporation
-
Fuda Cancer Hospital, GuangzhouCompleted
-
University Hospital Inselspital, BerneCantonal Hospital of St. Gallen; St. Claraspital AG; Cantonal Hospital of ZugTerminatedPancreatic CancerSwitzerland
-
Yonsei UniversityUnknownLocally Advanced Pancreatic CancerKorea, Republic of
-
University Hospital Inselspital, BerneTerminated
-
Assiut UniversityUnknown
-
University College London HospitalsUnknownProstate CancerUnited Kingdom
-
Poitiers University HospitalSport & Collection 2019WithdrawnCholangiocarcinoma | Interventional Imaging
-
Jewish General HospitalNot yet recruiting
-
University Hospital Inselspital, BerneTerminated
-
Memorial Sloan Kettering Cancer CenterCompletedColorectal Metastases to the LungUnited States